LPL Gene Test (Lipoprotein Lipase)

• Identify whether you carry LPL variants that alter lipoprotein lipase function, which can drive very high triglycerides in familial chylomicronaemia or more subtle changes in triglycerides, HDL, and LDL in common variants.
• Help explain patterns such as strikingly elevated triglycerides, low HDL, a family history of early pancreatitis, or "mixed" dyslipidaemia that does not fully match lifestyle, by revealing underlying lipase biology.
• Add context to coronary artery disease risk, since specific LPL polymorphisms such as D9N and N291S are associated with higher CAD risk, while others such as S447X and HindIII tend to be protective through more favourable lipid profiles.
• Inform personalised strategies around diet (particularly fat and refined carbohydrate), use of fibrates and omega‑3s, exercise, and, in severe cases, newer therapies and family screening.
• Clarify your baseline triglyceride clearance and remnant handling architecture alongside other lipid genes, so long term cardiovascular plans can be built on both genetics and real time lipids rather than population averages.

LPL encodes lipoprotein lipase, a secreted enzyme that is anchored to the luminal surface of capillary endothelium in adipose tissue, heart, and skeletal muscle. It functions as a homodimer and is recruited to its site of action by binding to GPIHBP1 and heparan sulfate proteoglycans on endothelial cells.

Functionally, LPL is a rate limiting enzyme in triglyceride metabolism. It hydrolyses triglycerides in circulating chylomicrons (from dietary fat) and very low density lipoproteins (VLDL, from hepatic production), releasing free fatty acids for uptake and storage or oxidation. LPL also acts as a ligand or bridging factor facilitating the uptake of lipoprotein remnants by hepatic receptors. Severe loss of function mutations cause familial chylomicronaemia syndrome, while milder variation influences common lipid traits.

At the biochemical level, LPL hydrolyses triglyceride molecules within chylomicrons and VLDL into free fatty acids and glycerol. The free fatty acids are taken up by nearby tissues such as muscle for energy or adipose tissue for storage, while the partially lipolysed lipoproteins become remnant particles that are cleared by the liver.

By governing the rate of triglyceride hydrolysis and remnant generation, LPL shapes several aspects of the lipid profile: fasting and postprandial triglyceride levels, HDL cholesterol through exchange of surface components, and the balance between VLDL, IDL, and LDL particles. LPL activity and mass correlate with fluctuations in triglycerides and HDL, and variation in LPL function contributes to disorders such as familial hyperchylomicronaemia, familial combined hyperlipidaemia, and common polygenic hypertriglyceridaemia.

LPL is central to triglyceride clearance, remnant metabolism, and atherogenesis. Biallelic rare loss of function variants in LPL cause familial chylomicronaemia syndrome, with extreme triglyceride elevation, eruptive xanthomas, lipaemia retinalis, and a high risk of recurrent acute pancreatitis from childhood. Heterozygous damaging variants can also produce severe hypertriglyceridaemia in some families and may act in a dominant fashion in certain contexts.

Beyond rare disease, common LPL polymorphisms influence triglyceride and HDL levels and coronary artery disease risk. D9N and N291S, which reduce catalytic function, are associated with higher triglycerides and increased CAD risk, while S447X and HindIII variants are generally associated with lower triglycerides, higher HDL, and reduced CAD risk. LPL sits alongside APOA5, APOC2, LMF1, and GPIHBP1 as a core gene cluster in primary hypertriglyceridaemia and is part of gene panels for familial hypertriglyceridaemia and combined hyperlipidaemia.

It is easy to assume that LPL testing and standard lipid panels tell you the same story, but they capture different layers of your biology. Lipid panels, apolipoproteins, and remnant cholesterol show how your lipids are behaving now; imaging and calcium scores show current arterial impact; LPL genotyping looks at inherited variants that set the baseline efficiency of triglyceride hydrolysis and remnant clearance across your life.

This distinction matters because you can have LPL variants that push triglycerides higher yet keep triglycerides and HDL in range through diet, exercise, and medication, and you can have high triglycerides with normal LPL genotype due to secondary causes such as obesity, alcohol, diabetes, or certain drugs. LPL results help distinguish between predominantly genetic and predominantly acquired hypertriglyceridaemia and refine risk in people whose lipid patterns are not fully explained by lifestyle.

The influence of LPL variants is strongly shaped by diet, body composition, metabolic health, and other genes rather than by the gene alone, which means you have meaningful room to change the trajectory. Several modifiable factors can either buffer or amplify any genetic tendency.

• Diet quality and macronutrient balance: High intakes of simple sugars, refined carbohydrates, and alcohol increase VLDL production and triglycerides, often unmasking LPL related susceptibility, while diets that emphasise whole foods, fibre, and appropriate fat quality can substantially reduce triglycerides.
• Body weight and insulin sensitivity: Central obesity and insulin resistance increase VLDL production and reduce HDL, amplifying the impact of LPL variants. Weight loss, strength training, and improved insulin sensitivity often move triglycerides more than genetics.
• Physical activity: Regular aerobic and resistance exercise increases LPL activity in muscle, enhances triglyceride clearance, and raises HDL, which can partly offset less favourable LPL genotypes.
• Other lipid genes and secondary causes: Coexisting variants in APOA5, APOC2, APOE, and others, as well as conditions such as uncontrolled diabetes, hypothyroidism, kidney disease, and drugs like corticosteroids or retinoids, can interact with LPL variants to drive high triglycerides or pancreatitis risk.
• Medication choices: Fibrates, omega‑3 fatty acids, and sometimes niacin or newer triglyceride lowering agents are used to target high triglycerides and remnant cholesterol, with LPL biology helping to explain why fibrates are especially effective in very high triglyceride states.

Yes, and this is common. Many people carry LPL variants, including D9N, N291S, HindIII, or S447X, without developing pancreatitis or overt cardiovascular disease. The effect sizes of common variants are modest and often only become clinically relevant when combined with other risk factors such as obesity, diabetes, poor diet, or smoking.

Even for familial LPL deficiency, heterozygotes may have a highly variable triglyceride phenotype. Some show significant hypertriglyceridaemia and pancreatitis, while others remain relatively mild, influenced by lifestyle, other genes, and coexisting conditions. This variability underlines the importance of viewing LPL status as one part of a broader cardiometabolic picture.

Common LPL genotypes mainly differ in how they affect enzyme synthesis, activity, and interaction with lipoproteins, which then shift triglyceride and HDL levels and cardiovascular risk.

• Severe loss of function variants (biallelic): Cause familial chylomicronaemia syndrome with near absence of functional LPL, extreme fasting and postprandial triglycerides, chylomicronaemia, and very high pancreatitis risk. These cases require strict fat restriction and specialised therapies.
• Heterozygous damaging variants: Can produce severe hypertriglyceridaemia and recurrent pancreatitis in some individuals and families, often in combination with secondary factors such as obesity and alcohol.
• D9N and N291S: Partial loss of function variants associated with higher triglycerides and increased coronary artery disease risk in meta analyses, especially when combined with other adverse lipid genes or high CRP in some subgroups.
• HindIII and S447X: Common polymorphisms linked to lower triglycerides, higher HDL, and reduced CAD risk in several populations, and generally considered protective lipid genotypes that improve remnant handling. S447X truncates the protein by two amino acids and appears to enhance LPL activity or secretion.

Other intronic and promoter variants also contribute to differences in LPL mass and activity and are part of the polygenic architecture of lipid traits identified in large genome wide studies.

For DNA based LPL testing, preparation is straightforward because your genotype does not change with diet or training. The key step is ensuring LPL is tested within an appropriate panel, such as a hypertriglyceridaemia or combined hyperlipidaemia gene panel, or a broader cardiometabolic or prevention panel, so that results can be interpreted in context and linked to a clear action plan.

LPL genotyping from blood or saliva does not require fasting. However, fasting is usually recommended for accompanying lipid panels and triglyceride measurements, and you should follow any specific instructions about timing, medication, and alcohol intake for those blood tests so they can be compared reliably over time.

An LPL test is most valuable when the result will change how you and your clinician manage triglycerides, pancreatitis risk, and cardiovascular prevention. It is less useful when ordered in isolation without considering lipid profiles, family history, and lifestyle.

• Severe or early onset hypertriglyceridaemia: If fasting triglycerides are very high or there is a history of pancreatitis, LPL testing as part of a hypertriglyceridaemia panel can clarify whether familial LPL deficiency or related monogenic disorders are present.
• Mixed dyslipidaemia with strong family history: In families with early heart disease or mixed lipid patterns that seem disproportionate to lifestyle, LPL genotyping can add nuance to risk assessment and justify more intensive prevention.
• Apparent "paradoxical" HDL and CRP combinations: In people with high HDL but high CRP or other concerning features, specific LPL polymorphisms such as D9N may highlight residual risk despite seemingly favourable lipids.
• Precision cardiometabolic prevention: For individuals designing a detailed prevention strategy, LPL status helps prioritise focus on triglycerides, remnant cholesterol, and fibrate or omega‑3 use within the broader plan.